| Title |
Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management
|
|---|---|
| Published in |
Psoriasis : Targets and Therapy, April 2017
|
| DOI | 10.2147/ptt.s108209 |
| Pubmed ID | |
| Authors |
Maria Vittoria Cannizzaro, Chiara Franceschini, Maria Esposito, Luca Bianchi, Alessandro Giunta |
| Abstract |
The risk of hepatitis B virus (HBV) reactivation (HBVr) in chronic HBV carriers, in occult HBV patients or in acute HBV patients affected by psoriasis and treated with anti-tumor necrosis factor (TNF)-α agents is a clinical practice issue to face with, particularly if the treatment has a long-term maintenance finality. The aims of this review are to examine the current knowledge on HBVr incidence in chronic HBV carriers and potential occult carriers undergoing therapy with biologics for the treatment of psoriasis and psoriatic arthritis; analyze the prophylactic measure to prevent HBV reactivation and define how to manage HBVr in patients treated with biologics. We searched through PubMed, Google Scholar and Scopus databases and evaluated all published manuscripts concerning HBVr in psoriatic patients, both plaque-type and psoriatic arthritis, in treatment with any indicated anti-TNF-α. Although anti-TNFs are considered moderate immunosuppressive drugs, the incidence of HBVr in psoriatic patients is lower compared to patients affected by other immune-mediated diseases treated with TNF inhibitors. HBV prophylaxis should be probably reserved to anti-HBs+/anti-HBc+ patients with a viral load <2000 IU/mL and alterations in serum liver enzymes, in order to prevent HBVr. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Philippines | 1 | 33% |
| France | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 5 | 17% |
| Student > Bachelor | 4 | 14% |
| Researcher | 3 | 10% |
| Student > Master | 3 | 10% |
| Student > Ph. D. Student | 2 | 7% |
| Other | 3 | 10% |
| Unknown | 9 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 48% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Physics and Astronomy | 1 | 3% |
| Computer Science | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 10 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 April 2017.
All research outputs
#15,879,822
of 25,584,565 outputs
Outputs from Psoriasis : Targets and Therapy
#54
of 79 outputs
Outputs of similar age
#179,944
of 324,452 outputs
Outputs of similar age from Psoriasis : Targets and Therapy
#1
of 1 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 36th percentile – i.e., 36% of other outputs scored the same or lower than it.
So far Altmetric has tracked 79 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 32.2. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,452 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them